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Abstract 
Background: A three‑day course of chloroquine remains a standard treatment of Plasmodium vivax infection in 
Thailand with satisfactory clinical efficacy and tolerability although a continuous decline in in vitro parasite sensitiv‑
ity has been reported. Information on the pharmacokinetics of chloroquine and its active metabolite desethylchlo‑
roquine are required for optimization of treatment to attain therapeutic exposure and thus prevent drug resistance 
development.
Methods: The study was conducted at Mae Tao Clinic for migrant worker, Tak province, Thailand. Blood samples 
were collected from a total of 75 (8 Thais and 67 Burmeses; 36 males and 39 females; aged 17–52 years) patients with 
mono‑infection with P. vivax malaria [median (95 % CI) admission parasitaemia 4898 (1206–29,480)/µL] following 
treatment with a three‑day course of chloroquine (25 mg/kg body weight chloroquine phosphate over 3 days). Whole 
blood concentrations of chloroquine and desethylchloroquine were measured using high performance liquid chro‑
matography with UV detection. Concentration–time profiles of both compounds were analysed using a population‑
based pharmacokinetic approach.
Results: All patients showed satisfactory response to standard treatment with a three‑day course of chloroquine 
with 100 % cure rate within the follow‑up period of 42 days. Neither recurrence of P. vivax parasitaemia nor appear‑
ance of P. falciparum occurred. A total of 1045 observations from 75 participants were included in the pharmacoki‑
netic analysis. Chloroquine disposition was most adequately described by the two‑compartment model with one 
transit compartment absorption model into the central compartment and a first‑order transformation of chloroquine 
into desethylchloroquine with an additional peripheral compartment added to desethylchloroquine. First‑order elimi‑
nation from the central compartment of chloroquine and desethylchloroquine was assumed. The model exhibited a 
strong predictive ability and the pharmacokinetic parameters were estimated with adequate precision.
Conclusion: The developed population‑based pharmacokinetic model could be applied for future prediction of 
optimal dosage regimen of chloroquine in patients with P. vivax infection.
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Background
Malaria remains one of the major global public health 
problems in the tropics and subtropics including South-
east Asia. The most recent World Malaria Report 
revealed an estimated 3.3 billion people at risk, 198 
million estimated cases, and 584,000 deaths, of which 
90 % occurred in Africa [1]. Apart from drug resistance 
in Plasmodium falciparum, the “sleeping giant” in the 
Greater Mekong subregion is P. vivax malaria, which has 
now become resistant to the blood schizontocide chlo-
roquine in some of the Southeast Asian countries, nota-
bly Indonesia [2, 3]. Chloroquine resistance is linked to 
increasing rates of anaemia and may be an important 
factor in severe P. vivax malaria [3]. The burden of P. 
vivax varies widely with the World Health Organization 
(WHO) estimating it being responsible for approximately 
12–22 million cases worldwide annually [1]. The disease 
is rarely life-threatening, but morbidity from a prolonged 
illness and the possibility of relapses from a persistent 
hepatic form (hypnozoite) which occurs more frequently 
with the tropical form of P. vivax found in Southeast 
Asian countries, is of major concern and cause consider-
able economic loss.
In Thailand, chloroquine and the tissue schizontocide 
primaquine have remained the mainstay treatment of P. 
vivax infection for more than 60 years with a conserved 
clinical efficacy of virtually 100  % [4–7]. To date, there 
has been no clinico-parasitological evidence of chloro-
quine resistant P. vivax in Thailand, although a trend in 
gradual decline of in vitro sensitivity to the drug has been 
documented in some areas of the country, particularly 
along the Thai-Myanmar border [8, 9]. It is possible that 
resistant levels may remain obviously below the threshold 
of detectability by the in  vivo assessment. The accumu-
lating reports of chloroquine resistant P. vivax in other 
parts of the world during the past three decades particu-
larly in Southeast Asian region such as Indonesia [10], 
Papua New Guinea [11–14], Irian Jaya [15–18], Myanmar 
[19–21] and Vietnam [22], emphasize the need for closely 
and continuously monitoring clinical efficacy in conjunc-
tion with in vitro sensitivity with confirmed adequacy of 
anti-malarial systemic drug exposure [23]. The informa-
tion obtained would facilitate the early recognition of 
treatment failures and adjustment of treatment policy. 
Optimization of chloroquine treatment is essential to 
attain therapeutic exposure and thus prevent resistance 
development to the drug. Inadequate drug exposure may 
lead to subtherapeutic concentrations of chloroquine 
and an increased risk of severe vivax malaria as well as 
the development of resistant strains of P. vivax. The aim 
of the study was to investigate the pharmacokinetics of 
chloroquine and its active metabolite desethylchloro-
quine following treatment with a three-day standard 
course of chloroquine in patients with P. vivax infection 
on the Thai-Myanmar border.
Methods
Patients and study design
The study was conducted at Mae Tao clinic for migrant 
workers, Tak Province, Thailand. Prior to study, approval 
of the study protocol was obtained from the Ethics Com-
mittee of the Ministry of Public Health of Thailand. The 
study was part of the clinical study conducted during 
2010–2011 to monitor the clinical efficacy and in  vitro 
sensitivity of P. vivax isolates to chloroquine in an area 
along the Thai-Myanmar border [7]. Written informed 
consents were obtained from all patients before study 
participation. A total of 75 (8 Thai and 67 Burmese; 36 
males and 39 females; aged 17–52 years) patients with P. 
vivax mono-infection [median (95 % CI) admission para-
sitaemia 4898 (1206–29,480)/µL] were included in the 
study [7]. In brief, patients were treated with the stand-
ard three-day chloroquine (Government Pharmaceutical 
Organization of Thailand, 250 mg chloroquine phosphate 
per tablet) regimen given at a total dose of 25 mg base/kg 
body weight over 3 days (10 and 5 mg/kg at 0 and 6–12 h 
on day 0, and 5 mg/kg each on day 1 and day 2) and pri-
maquine (Government Pharmaceutical Organization 
of Thailand, 15  mg base per tablet) given at daily doses 
of 15 mg base/kg body weight daily for 14 days starting 
from the second day (day 1) of chloroquine treatment. 
Chloroquine and primaquine dose administration during 
the first 3 days (days 0, 1 and 2) were administered with a 
glass of 250 mL drinking water under the supervision of 
a medical staff. Patients were closely observed for at least 
30 min after drug ingestion.
All patients were admitted to the clinic during the 
course of treatment or until signs and symptoms of 
malaria disappeared. Prior to treatment, a blood sample 
(5 mL) was collected from each patient for in vitro sensi-
tivity testing of P. vivax isolates to chloroquine and deter-
mination of baseline anti-malarial drug concentrations 
(chloroquine and its active plasma metabolite desethyl-
chloroquine). Patients were requested to return for fol-
low-up on days 7, 14, 21, 28, 35 and 42, or at any time 
if fever or symptoms suggestive of malaria developed. At 
each visit, a parasite count was performed (Giemsa stain), 
and a detailed questionnaire for general symptoms was 
recorded. Malaria blood smears were obtained on enroll-
ment and thereafter, twice daily until two consecutive 
slides were confirmed to be negative, as well as at every 
follow-up visit. Thick films were screened for 200 oil-
immersion fields before declaring a slide negative. Asex-
ual parasites and gametocytes were separately counted 
against 200 white blood cells (WBCs); if the parasite 
density was too numerous to count on the thick film, the 
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number of parasites per 2000 red blood cells (RBCs) on 
the thin film were counted. Clinical efficacy of the three-
day course of chloroquine was evaluated in the group of 
patients who completed the 42-day follow-up period. The 
classification of the therapeutic outcome was according 
to the WHO protocol [23].
Blood sampling and drug analysis
Blood samples were collected at specified time points, 
i.e., pre-dose and at 1, 6, 12, 24, 25, 36, 48 and 49  h 
after the first dose for measurement of chloroquine and 
desethylchloroquine concentrations. Blood samples were 
also collected during the follow-up period at day 7, 14, 
21, 28, 35 and 42 after the initiation of the treatment. 
Concentrations of chloroquine and desethylchloroquine 
in plasma samples were measured using high perfor-
mance liquid chromatography according to the method 
of Cheomung and colleagues [24]. The lower limit of 
quantification (LOQ) of the assay was 2 ng/mL for both 
chloroquine and desethylchloroquine. The assay accu-
racy (expressed as % relative error: % RE) of the quality 
control samples used during the sample analysis for both 
chloroquine and desethylchloroquine ranged from 0.25 
to 5.7 %. The assay precision (expressed as coefficient of 




Concentration–time data of chloroquine and desethyl-
chloroquine, transformed into their natural logarithms, 
were analysed using the mixed-effects modelling in 
NONMEM® (version 7.12; ICOM Development Solu-
tions, Ellicot City, MD, USA) and the output results and 
graphical plots were handled using the statistical analysis 
programs R (version 2.15.1; Free Software Foundation, 
Boston, MA, USA) and R-package Xpose (version 4.3.5; 
Uppsala University, Uppsala, Sweden). The observations 
that were below the limit of quantification were excluded 
from the pharmacokinetic analysis. The first-order con-
ditional estimation (FOCE) method was used through-
out the modeling. Model evaluation was based on visual 
inspection of diagnostic plots, precision of parameters 
and the objective function value (OFV; proportional to 
−2 Log likelihood) [25]. For nested models, the differ-
ence in OFV is approximately Chi squared distributed 
and it can therefore be used in model discrimination.
For a one parameter difference between models, 
3.84 correspond to a p value of 0.05. Population phar-
macokinetic models were constructed to evaluate the 
concentration–time data for chloroquine and deseth-
ylchloroquine and to identify any covariates that could 
describe between subject variability (BSV). A metabolite 
model was implemented to describe the pharmacoki-
netics of chloroquine and desethylchloroquine. One, 
two-and three compartment models were initially inves-
tigated both for the parent drug and metabolite. Different 
models for the elimination of chloroquine and its metab-
olite were evaluated. A first-order absorption model 
and a transit compartment absorption model with 1–10 
transit compartments were investigated to describe the 
absorption of chloroquine. Relative bioavailability was 
added with a typical value of 100 % with an estimate of 
between-subject variability. Between-subject variability 
was added exponentially, resulting in log-normal distrib-
uted parameters:
where Pi is the true value of the parameter for the indi-
vidual and Pp is the typical or population value of the 
parameter. Pp is the fixed effect parameter estimated 
from the structural model and ηi represents the differ-
ence between Pi and Pp.
An additive residual variability (RUV) model was 
applied according to:
where Cobs is the observed drug or metabolite concentra-
tion and Cp is the concentration predicted by the model 
and εad represents the difference between these values. 
An additive model on log-transformed data is equivalent 
to an exponential model.
The most adequate structural model with random 
effects (base model) was further developed to include 
covariates using a stepwise forward addition (p =  0.05) 
of covariates, followed by a stepwise backward elimina-
tion procedure (p  =  0.001). Relationships between all 
parameters estimated in the base model and covari-
ates, i.e., body weight (BW), age, sex, parasite clearance 
time (PCT) and fever clearance time (FCT) were evalu-
ated. The covariate was retained in the final model if its 
removal resulted in an increase in the objective function 
of ≥10.83 points (p < 0.001) from the full model. BW was 
applied as a covariate on all CL and V values as a power 
model according to equation:
where Pt is the typical population value of the param-
eter for the population; θ1 represents the estimate of 
P in an individual with median BW; and θ2 is the frac-
tional change in Pt with each kilogram change in BW 
from median BW. BW was allometrically scaled and θ2 




Cobs = Cp + εad
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The covariate model for continuous covariates such as 
FCT was exemplified by the following equation:
where Pt is the typical value of parameter P; θ1 represents 
the estimate of P in an individual with median FCT; and 
VPt = θ1 · [1 + θ2 × (FCT − median FCT)]
θ2 the fractional change in P with each change in unit of 
FCT from median FCT.
All clearance and distribution parameters are reported 
as the ratio of the parameter and bioavailability since oral 
dosing was not accompanied by an intravenous dose. The 
pharmacokinetic population parameters estimated from 
Fig. 1 A two‑compartment model (central and peripheral) with a one transit compartment model for the absorption of chloroquine into the 
central compartment and a first‑order transformation of chloroquine into desethylchloroquine with an additional peripheral compartment added 























































Fig. 2 Goodness of fit plots of chloroquine. Plots of the observed versus population predicted concentrations (a) and observed versus individual 
predicted concentrations (b). Weighed individual residuals versus individual predictions (c) and weighed residuals versus time (d). The black line is a 
non‑parametric smoother describing the trend and the black line is the line of unity
Page 5 of 9Höglund et al. Malar J  (2016) 15:129 
the final covariate model were used to calculate terminal 
half-life for chloroquine and desethylchloroquine.
Bootstrap diagnostics were performed using 1000 re-
sampled datasets. The precision was described as a rela-
tive standard error. A visual predictive check (VPC) is a 
tool for the evaluation of the predictive ability and the 
appropriateness of a model and was done by performing 
simulations of 1000 observations at each time point for 
the real observations in the data set with the final covari-
ate model. The median and 95 % prediction intervals of 
the simulated data and the true observations were plot-
ted against time. The predictive ability of the model was 
assumed to be adequate if less than 10 % of the observed 
concentrations fell outside the prediction interval.
Results
A total of 75 patients with P. vivax malaria were included 
in the analysis. All had completed a 42  days follow-up 
period. All patients showed good response following 
treatment with no reappearance of parasitaemia. The 
treatment was well-tolerated. All patients showed sat-
isfactory response to treatment with 100  % cure rate 
within the follow-up period of 42 days. Median (95 % CI) 
parasite clearance time (PCT: the time taken for the par-
asite count to fall below the level of microscopic detec-
tion) and fever clearance time (FCT: the time taken for 
the temperature to return to normal, i.e., <37.3 °C) were 
30 (18–36) and 24 (12–42) hours, respectively. Neither 
recurrence of P. vivax parasitaemia nor appearance of P. 
falciparum occurred.
Population pharmacokinetic models
The final data set included in the pharmacokinetic mod-
eling consisted of 1405 observations of both chloroquine 
and desethylchloroquine from 75 individuals (less than 
5  % of the samples below the lower limit of quantifica-
tion). The final model for chloroquine and desethylchlo-
roquine following a three-day chloroquine dose regimen 
was a two-compartment model for both chloroquine and 
its metabolite (p < 0.01) with a one transit compartment 
model for the absorption of chloroquine (Fig.  1). The 
parameter describing the transformation of chloroquine 
into desethylchloroquine (CLm) was fixed to 18 % of the 
transformation clearance from parent drug to metabo-
lite [26]. One transit compartment described the absorp-
tion phase adequately and the relative bioavailability 
were retained in the final model (p  <  0.05). In the final 
model, BSV was kept on the apparent volume of distri-
bution of desethylchloroquine, relative bioavailability 
and the apparent volume of distribution in the peripheral 
compartment of chloroquine and desethylchloroquine. 
Adding between-subject variability on the mean tran-
sit time resulted in high relative standard errors on this 
parameter (149 %, based on 59 successful bootstraps runs 
out of 100) and was not kept in the model.
No covariates were added in the final model. FCT was 
a significant covariate for VP CQ/F in the forward step but 
was not retained in the backward step. The basic good-
ness of fit plots exhibited adequate description of the 
data (Fig. 2). Parameter estimates and their precision for 
the final model and estimates from the non-parametric 
bootstrap are listed in Table  1. The calculated half-lives 
are presented in Table  1. The visual predictive check 
Table 1 Objection function values, parameter estimates 
and  their precision for  the final covariate model and  the 
bootstrap. The bootstrap estimates are derived from  the 
final covariate model
MTT mean transit time of the absorption, CLCQ/F apparent clearance 
of CQ for transformation into desethylchloroquine, VC CQ/F apparent 
volume of distribution for CQ central compartment, VP CQ/F apparent 
volume of distribution for CQ peripheral compartment, QCQ/F apparent 
intercompartmental clearance for CQ, t1/2CQ half-life of chloroquine, KFCT 
constant describing the fraction of change in peripheral volume of distribution 
of chloroquine with each unit of fever clearance time, CL DCQ/F apparent 
clearance of DCQ, VC DCQ/F apparent volume of distribution for DCQ central 
compartment, VP DCQ/F apparent volume of distribution of DCQ peripheral 
compartment, QDCQ/F apparent intercompartmental clearance for DCQ, t1/2 
half-life of desethylchloroquine. BSV is the between subject variability
a Listed as estimates and their relative standard errors (RSE; %) in parenthesis. 
RSE is calculated based 603 succesfull bootstrap runa (out of 1000) according 
to: 100 × Standard deviation/Average, 95 % CI is the 95 % confidence interval of 
the bootstrap parameter estimates
b Listed as coefficient of variation (CV; %) and their RSE (%) in parenthesis
c Listed as CV (%) and their RSE (%) in parenthesis
Parameter Estimated from




 MTT (h) 0.773 (43.1) 0.809–2.38
 CLCQ/F (L/h) 6.13 (3.40) 5.74–6.55
 VC CQ/F (L) 468 (16.0) 137–529
 VP CQ/F (L) 1600 (5.21) 1470–1800
 QCQ/F (L/h) 37.7 (18.9) 31.1–69.0
 t1/2 CQ (days) 10.7
 CLDCQ/F (L/h) 2.04 (3.50) 1.90–2.18
 VC DCQ/F (L) 2.27 (14.1) 1.62–2.90
 VP DCQ/F (L) 566,257 (14.4) 198–341
 QDCQ/F (L/h) 31.46 (12.3) 1.11–1.83
 t1/2 DCQ (days) 8.74
Interindividual variabilityb
 BSV VC DCQ 48.7 (47.5) 17.9–71.1
 BSV VP CQ 20.0 (61.6) 8.25–31.9
 BSV VP DCQ 86.8 (30.5) 49.1–116
 BSV F 19.4 (31.7) 13.1–25.4
Residual variabilityc
 Proportional error CQ 0.401 (5.34) 0.360–0.444
 Proporional error 
DCQ
0.431 (4.97) 0.393–0.479
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indicated a strong predictive ability of the model for the 
dataset where less than 10  % of the observations were 
outside the 95 % prediction interval (Figs. 3, 4).
Discussion
Chloroquine remains the anti-malarial drug which is 
widely used in the tropics due to its safety, availability 
and low cost. The drug has now been rendered com-
pletely ineffective for treatment and prophylaxis of P. 
falciparum, but for P. vivax, P. ovale and P. malariae, it 
is still in use. For optimization of dosage regimen of 
chloroquine for the treatment or prophylaxis of these 
infections, plasma/blood drug concentrations and phar-
macokinetic analysis are necessary. Nevertheless, the 
pharmacokinetics of chloroquine is not well understood. 
Previous studies involved small number of subjects and 
in some cases, with limitation of sensitivity of analyti-
cal methods and pharmacokinetic modeling techniques 
[27–32]. In addition, a wide range of inter-individual 
variability in the estimated pharmacokinetic parameters 
hurdles optimization of dose regimen of chloroquine for 
both clinical applications particularly in patients infected 
with P. vivax.
The large variability between individuals in the phar-
macokinetic parameters of chloroquine makes popu-
lation approaches a convenient method to assess the 
pharmacokinetic characteristics of the drug. Inclusion 
of concentration data of the active metabolite desethyl-
chloroquine in the analysis is of further relevance as this 
metabolite has been shown to exhibit significant anti-
malarial activity [33]. The final covariate model included 
a two-compartmental disposition for both chloroquine 
and desethylchloroquine with an adequate accuracy 
in the estimated parameters. The multi-exponential 
declines for both parent compound and metabolite are 
in consistency with previous reports [34–37]. For chlo-
roquine, the estimates of absorption rate constant, the 
total apparent volume of distribution, and elimination 
half-life of chloroquine are in agreement with previously 
reported values. The apparent elimination clearance is 
lower compared to previous studies. This is probably due 






















































Fig. 3 Goodness of fit plots of desethylchloroquine. Plots of the observed versus population predicted concentrations (a) and observed versus indi‑
vidual predicted concentrations (b). Weighed individual residuals versus individual predictions (c) and weighed residuals versus time (d). The black 
line is a non‑parametric smoother describing the trend and the black line is the line of unity
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of desethylchloroquine parameters such as apparent 
elimination clearance, apparent total volume of distri-
bution and elimination half-life were relatively lower 
than reported values [26, 34–39]. The fact that reports 
of desethylchloroquine parameter estimations have been 
limited, might offer a skewed distribution of the values of 
the parameters. The underestimation of the parameters 
could also be due to the fixation of CLm to 18 %, an esti-
mation based on the fraction desethylchloroquine of the 
total chloroquine dose recovered in urine. In the study 
reported by Karunajewa et  al. [35], the same approxi-
mation of CLm was used and might also have underes-
timated their obtained pharmacokinetic parameters of 
desethylchloroquine. Besides desethylchloroquine, bide-
sethylchloroquine is produced by secondary metabolism 
of desethylchloroquine [42] and the formation of the 
third metabolite might also be a result of further metab-
olism of bidesethylchloroquine. This suggests that the 
amount of chloroquine transformed into desethylchloro-
quine should be assessed by estimating the amount of all 
secondary metabolites and including them in the estima-
tion of the fraction desethylchloroquine formed. As chlo-
roquine is metabolized up to 30–50 % by the liver and the 
mainly formed metabolites are (mono) desethylchloro-
quine and bidesethylchloroquine, the fraction of deseth-
ylchloroquine formed needs to be reassessed.
The quantification of a relationship between the drug 
concentration and response (pharmacokinetic-pharma-
codynamic relationship) enables the identification of drug 
target levels. Biomarkers of response for the treatment of 
malaria have been collected and since the target of action 
of chloroquine is in infected red blood cells, it would 
most probably be uncomplicated and straightforward to 
characterize the relationship between blood concentra-
tions and parasitaemia. The concentrations of chloro-
quine or desethylchloroquine associated with adequate 
treatment of P. vivax malaria have not been established 
rigorously. The minimum effective concentration (MEC) 
of chloroquine in plasma or serum of 15–30 ng/mL or in 
whole blood of 90  ng/mL have been suggested [45, 46]. 
Furthermore, patients with parasitaemia in the presence 
of chloroquine and desethylchloroquine concentration 
in whole blood of greater than 100 ng/mL is considered 
chloroquine resistant [16, 47, 48]. Unfortunately, this 
threshold level could not be determined in this group 
of patients as none had treatment failure following this 
standard regimen of chloroquine. In a recent study con-
ducted in Bolivia, South America, chloroquine resistance 
P. vivax was reported in 6.5 % patients [49]. Chloroquine 
and desethylchloroquine in whole blood on day 7 and the 
day of parasite recrudescence in ten patients were 197–
535 and 75–223 ng/mL, respectively. Six out of these ten 
patients has drug concentrations above the MEC.
Conclusion
A population pharmacokinetic model for chloroquine 
incorporating desethylchloroquine has been developed 
and validated with an adequate precision on the param-
eters. The determination of a more realistic fraction of 
desethylchloroquine formed would also be needed for 
future studies. This would create the possibility of more 
optimal exposure prediction for both compounds and 
Fig. 4 Plots from the visual predictive check for chloroquine (a) and 
desethylchloroquine (b) observations. The middle solid lines represent 
the median of simulated predictions by the final model. The dashed 
black lines represent the corresponding percentiles for the true 
observations. The black dots are the true observations and the grey 
shaded areas are the 95 % confidence intervals for the simulations. 
The decline in the upper percentiles of desethylchloroquine is due to 
base line values in the subjects
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optimization of malaria treatment in P.vivax monoinfec-
tion. Prompt and effective treatment would lead to effica-
cious killing of the malaria parasites and the prevention 
of resistance development to chloroquine.
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